118 related articles for article (PubMed ID: 37184520)
1. Vitamin D Status Is Associated With Immune Checkpoint Inhibitor Efficacy and Immune-related Adverse Event Severity in Lung Cancer Patients: A Prospective Cohort Study.
You W; Liu X; Tang H; Lu B; Zhou Q; Li Y; Chen M; Zhao J; Xu Y; Wang M; Qian J; Tan B
J Immunother; 2023 Jul-Aug 01; 46(6):236-243. PubMed ID: 37184520
[TBL] [Abstract][Full Text] [Related]
2. Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer.
Cunningham-Bussel A; Wang J; Prisco LC; Martin LW; Vanni KMM; Zaccardelli A; Nasrallah M; Gedmintas L; MacFarlane LA; Shadick NA; Awad MM; Rahma O; LeBoeuf NR; Gravallese EM; Sparks JA
Arthritis Rheumatol; 2022 Mar; 74(3):527-540. PubMed ID: 34397169
[TBL] [Abstract][Full Text] [Related]
3. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
[TBL] [Abstract][Full Text] [Related]
4. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
[TBL] [Abstract][Full Text] [Related]
5. Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer.
Akamatsu H; Murakami E; Oyanagi J; Shibaki R; Kaki T; Takase E; Tanaka M; Harutani Y; Yamagata N; Okuda Y; Furuta K; Sugimoto T; Teraoka S; Hayata A; Tokudome N; Ozawa Y; Mori K; Koh Y; Yamamoto N
Oncologist; 2020 Apr; 25(4):e679-e683. PubMed ID: 32297443
[TBL] [Abstract][Full Text] [Related]
6. Vitamin D metabolism pathway polymorphisms are associated with efficacy and safety in patients under anti-PD-1 inhibitor therapy.
Luo J; Chen H; Ma F; Xiao C; Sun B; Liu Y; Tang H; Yang Y; Liu W; Luo Z
Front Immunol; 2022; 13():937476. PubMed ID: 36172344
[TBL] [Abstract][Full Text] [Related]
7. Lipidomics reveals immune-related adverse events in NSCLC patients receiving immune checkpoint inhibitor.
Yu J; Xiong F; Xu Y; Xu H; Zhang X; Gao H; Li Y
Int Immunopharmacol; 2024 Jan; 127():111412. PubMed ID: 38160567
[TBL] [Abstract][Full Text] [Related]
8. Systematic vitamin D supplementation is associated with improved outcomes and reduced thyroid adverse events in patients with cancer treated with immune checkpoint inhibitors: results from the prospective PROVIDENCE study.
Bersanelli M; Cortellini A; Leonetti A; Parisi A; Tiseo M; Bordi P; Michiara M; Bui S; Cosenza A; Ferri L; Giudice GC; Testi I; Rapacchi E; Camisa R; Vincenzi B; Caruso G; Rauti AN; Arturi F; Tucci M; Santo V; Ricozzi V; Burtet V; Sgargi P; Todeschini R; Zustovich F; Stucci LS; Santini D; Buti S
Cancer Immunol Immunother; 2023 Nov; 72(11):3707-3716. PubMed ID: 37638980
[TBL] [Abstract][Full Text] [Related]
9. Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer.
Dolladille C; Ederhy S; Sassier M; Cautela J; Thuny F; Cohen AA; Fedrizzi S; Chrétien B; Da-Silva A; Plane AF; Legallois D; Milliez PU; Lelong-Boulouard V; Alexandre J
JAMA Oncol; 2020 Jun; 6(6):865-871. PubMed ID: 32297899
[TBL] [Abstract][Full Text] [Related]
10. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162
[TBL] [Abstract][Full Text] [Related]
11. Immune-related adverse events are associated with improved response, progression-free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors.
Foster CC; Couey MA; Kochanny SE; Khattri A; Acharya RK; Tan YC; Brisson RJ; Leidner RS; Seiwert TY
Cancer; 2021 Dec; 127(24):4565-4573. PubMed ID: 34547103
[TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint Inhibitor Rechallenge Safety and Efficacy in Stage IV Non-Small Cell Lung Cancer Patients After Immune-Related Adverse Events.
Guo M; VanderWalde AM; Yu X; Vidal GA; Tian GG
Clin Lung Cancer; 2022 Dec; 23(8):686-693. PubMed ID: 36050243
[TBL] [Abstract][Full Text] [Related]
13. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer.
Allouchery M; Lombard T; Martin M; Rouby F; Sassier M; Bertin C; Atzenhoffer M; Miremont-Salame G; Perault-Pochat MC; Puyade M;
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428586
[TBL] [Abstract][Full Text] [Related]
14. A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer.
Yan YD; Cui JJ; Fu J; Su YJ; Chen XY; Gu ZC; Lin HW
Front Immunol; 2021; 12():760737. PubMed ID: 34925331
[TBL] [Abstract][Full Text] [Related]
15. Immune-related adverse events as potential surrogates of immune checkpoint inhibitors' efficacy: a systematic review and meta-analysis of randomized studies.
Amoroso V; Gallo F; Alberti A; Paloschi D; Ferrari Bravo W; Esposito A; Cosentini D; Grisanti S; Pedersini R; Petrelli F; Berruti A
ESMO Open; 2023 Apr; 8(2):100787. PubMed ID: 36842300
[TBL] [Abstract][Full Text] [Related]
16. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
17. Disease progression status during initial immune checkpoint inhibitor (ICI) affects the clinical outcome of ICI retreatment in advanced non-small cell lung cancer patients.
Torasawa M; Yoshida T; Takeyasu Y; Shimoda Y; Tateishi A; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Takahashi K; Ohe Y
Cancer Med; 2023 Jun; 12(11):12388-12401. PubMed ID: 37062059
[TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis.
Zhao Q; Zhang J; Xu L; Yang H; Liang N; Zhang L; Zhang F; Zhang X
Front Immunol; 2021; 12():730320. PubMed ID: 34646270
[TBL] [Abstract][Full Text] [Related]
19. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
[TBL] [Abstract][Full Text] [Related]
20. Association between immune-related adverse events and the efficacy of PD-1 inhibitors in advanced esophageal cancer.
Qin W; Yang L; Fan B; Zou B; Duan Y; Li B; Wang L
Front Immunol; 2022; 13():931429. PubMed ID: 36248782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
